Tagged with Clinical Trials

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Lilly’s US$345M AI-driven BsAb licensing deal with XtalPi, IVACTA’s RMB 100M fundraising for in vivo CAR-T therapies, Vigonvita’s HKD 5.873B IPO with 4,974x oversubscription, and Neurocrine’s US$881M global licensing of TransThera’s NLRP3 inhibitors. Clinical breakthroughs feature HighTide’s positive Phase…

China This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Qyuns Therapeutics’ US$1.07 billion licensing deal with Roche, Healthgen Biotech’s RMB 42 billion STAR Market IPO, and Immunofoco’s Series B+ funding for CAR-T therapies. Clinical updates include Bioheng’s CAR-T success in autoimmune diseases, Qyuns’ Phase III results for Crusekitug…

Taiwan After more than two decades in Silicon Valley, Dr Jeng Her returned to Taiwan with a bold ambition: to help transform its emerging biotech sector into a globally recognised force in antibody innovation. As Founder and CEO of AP Biosciences, he has positioned the company at the forefront of bispecific…

China This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Innovent’s record-breaking US$11.4 billion BsAb and ADC partnership with Takeda, DualityBio’s plans for a STAR Market IPO after positive HER2 ADC Phase III data, Biokin’s US$250 million milestone payment from BMS and HKEX IPO approval, and Haixi Pharma’s 36%…

Taiwan Dr Chiu-Heng Chen (John), CEO of LaunXP, brings a unique perspective to oncology drug development shaped by his personal experience with cancer during his PhD in the UK. Holding advanced degrees from British and Taiwanese institutions in tumour oncology, he founded LaunXP in 2015 to bridge academia and clinical practice,…

LatAm Sandra Ramirez, Latam Area Lead, Astellas Pharma, outlines the company’s strong momentum across Mexico, Colombia, Argentina, and Chile, highlighting regulatory innovation, strategic partnerships, and expanded patient access. She discusses the strategic importance of Mexico’s new Global Capability Centre, the region’s growing role in clinical research, and how diversity, integrity, and…

France Born from a serendipitous scientific discovery in Montpellier, Abivax has evolved into one of France’s most promising global biotechs. Led by CEO Marc de Garidel, the company is harnessing its pioneering miR-124-based therapy, obefazimod, to redefine treatment possibilities in inflammatory bowel disease through an entirely new, immune-balancing mechanism of action.…

France Created in the wake of COVID-19, the Agence de l’Innovation en Santé (AIS), part of the Secrétariat Général pour l’investissement – a Prime Minister department, has rapidly positioned itself at the heart of France’s health innovation strategy, driving progress in areas such as bioclusters, prevention, clinical research, and artificial intelligence.…

Colombia Francisco Rossi, Director of Colombia’s National Food and Drug Surveillance Institute (INVIMA), discusses the agency’s ongoing transformation to become a faster, more transparent, and globally recognised regulator. Since his return in 2024, Rossi has prioritised reducing backlogs, launching the digital platform InvimÁgil, and refocusing INVIMA on public health surveillance. He…

LatAm Sarah Aiosa, SVP and President of MSD (known as Merck & Co. in the U.S. and Canada) for Latin America, highlights nearly four years of strong growth built on a clear mission to expand access to healthcare. Under her leadership, MSD has advanced vaccines, oncology treatments, and clinical research in…

UK Originally published in the October 2025 edition of DIA’s Global Forum magazine, this article — authored by Mandy Budwal-Jagait, Kingyin Lee, Maria Urdaneta-Abate, Hedwig Ganguly, Rachel Mead, and Louisa Obillo of the UK Medicines and Healthcare products Regulatory Agency (MHRA), together with Catherine Blewett of the Health Research Authority (HRA)…

China This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta highlights CF PharmTech’s HKEX listing with a 227% grey market premium, Eccogene’s HKEX IPO filing at a US$500M valuation, Zenas Bio’s US$2B licensing deal with InnoCare, and Nuruit Medical’s RMB 800M Series D financing. Clinical updates include Henlius’s…